5,419 results match your criteria Neoplasms of the Endocrine Pancreas


Serum chromogranin A for the diagnosis of gastroenteropancreatic neuroendocrine neoplasms and its association with tumour expression.

Oncol Lett 2019 Feb 5;17(2):1497-1504. Epub 2018 Dec 5.

Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, P.R. China.

The aim of the present study was to assess the clinical value of serum chromogranin A (CgA) levels in patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) and to compare them with tumour expression of CgA. A total of 109 consecutive patients with confirmed GEP-NENs were enrolled in this prospective study between December 2012 and August 2016, including 73 patients with primary or recurrent GEP-NENs and 36 patients with GEP-NENs that were treated following surgery. Furthermore, 30 patients with benign gastrointestinal diseases and 30 healthy volunteers served as control groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2018.9795DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341841PMC
February 2019
1 Read
0.987 Impact Factor

The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice.

Endocrine 2019 Jan 11. Epub 2019 Jan 11.

The ARDEN NET Centre, University Hospitals Coventry & Warwickshire NHS Trust, Coventry, UK.

Purpose: To study the evolution and optimal management of metastatic bone disease (mBD) in patients with neuroendocrine neoplasms (NENs).

Methods: Seventy-four patients were recruited from four NEN centers in this observational multicenter study.

Results: Pancreas and small bowel were the most common primaries (30 and 27%, respectively). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-019-01838-8DOI Listing
January 2019
1 Read
3.527 Impact Factor

A case of malignant insulinoma responsive to somatostatin analogs treatment.

BMC Endocr Disord 2018 Dec 27;18(1):98. Epub 2018 Dec 27.

Endocrine Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Careggi University Hospital, Florence, Italy.

Background: Insulinoma is a rare tumour representing 1-2% of all pancreatic neoplasms and it is malignant in only 10% of cases. Locoregional invasion or metastases define malignancy, whereas the dimension (> 2 cm), CK19 status, the tumor staging and grading (Ki67 > 2%), and the age of onset (> 50 years) can be considered elements of suspect.

Case Presentation: We describe the case of a 68-year-old man presenting symptoms compatible with hypoglycemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12902-018-0325-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307122PMC
December 2018
2 Reads

Deficiency of VCP-Interacting Membrane Selenoprotein (VIMP) Leads to G1 Cell Cycle Arrest and Cell Death in MIN6 Insulinoma Cells.

Cell Physiol Biochem 2018 7;51(5):2185-2197. Epub 2018 Dec 7.

Department of Medicine, The University of Chicago, Chicago, Illinois,

Background/aims: VCP-interacting membrane selenoprotein (VIMP), an ER resident selenoprotein, is highly expressed in β-cells, however, the role of VIMP in β-cells has not been characterized. In this study, we studied the relationship between VIMP deficiency and β-cell survival in MIN6 insulinoma cells.

Methods: To determine the role of VIMP in β-cells, lentiviral VIMP shRNAs were used to knock down (KD) expression of VIMP in MIN6 cells. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/495865
Publisher Site
http://dx.doi.org/10.1159/000495865DOI Listing
January 2019
2 Reads

Volumetric decrease of pancreas after abdominal irradiation, it is time to consider pancreas as an organ at risk for radiotherapy planning.

Radiat Oncol 2018 Dec 3;13(1):238. Epub 2018 Dec 3.

Department of Radiation Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.

Background: Volumetric shrinkage of normal tissues such as salivary glands, kidneys, hippocampus are observed after radiotherapy. We aimed to assess the alterations in pancreatic volume of patients who received abdominal radiotherapy and define pancreas as an organ at risk for radiation treatment planning.

Material-methods: Forty-nine patients operated for gastric adenocarcinoma who received adjuvant abdominal radiotherapy were in the study group, 27 patients with early stage disease who did not need adjuvant treatment after surgery comprised the control group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13014-018-1189-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276196PMC
December 2018
3 Reads

Leptomeningeal metastases of a well-differentiated neuroendocrine tumour: a rare entity.

BMJ Case Rep 2018 Nov 3;2018. Epub 2018 Nov 3.

Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

A 73-year-old man, without any medical history, had presented with dark urine and pale stool without pain. Diagnostic imaging revealed a tumour in the pancreas with liver metastases. Histopathological examination showed a well-differentiated pancreatic neuroendocrine tumour. Read More

View Article

Download full-text PDF

Source
http://casereports.bmj.com/lookup/doi/10.1136/bcr-2018-22655
Publisher Site
http://dx.doi.org/10.1136/bcr-2018-226557DOI Listing
November 2018
15 Reads

The epithelial-mesenchymal transition induces aggressivity of mucinous cystic neoplasm of the pancreas with neuroendocrine component: An immunohistochemistry study.

Pathol Res Pract 2019 Jan 23;215(1):82-89. Epub 2018 Oct 23.

Department of Pathology, University of Medicine, Pharmacy, Sciences and Technology, Targu Mures, Romania.

Background: Pancreatic mucinous cystic neoplasms (MCN) are rare tumors that are usually diagnosed in females.

Materials And Methods: In our department, only four of the 109 consecutive cases of pancreatic tumors (3.67%) were diagnosed as MCNs. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03440338183107
Publisher Site
http://dx.doi.org/10.1016/j.prp.2018.10.019DOI Listing
January 2019
13 Reads

Gene Therapy for Pancreatic Diseases: Current Status.

Int J Mol Sci 2018 Oct 31;19(11). Epub 2018 Oct 31.

Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757, Aasahimachi-Dori, Chuo-Ku, Niigata 951-8510, Japan.

The pancreas is a key organ involved in digestion and endocrine functions in the body. The major diseases of the pancreas include pancreatitis, pancreatic cancer, cystic diseases, pancreatic divisum, islet cell tumors, endocrine tumors, diabetes mellitus, and pancreatic pain induced by these diseases. While various therapeutic methodologies have been established to date, however, the improvement of conventional treatments and establishment of novel therapies are essential to improve the efficacy. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/1422-0067/19/11/3415
Publisher Site
http://dx.doi.org/10.3390/ijms19113415DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275054PMC
October 2018
7 Reads

Prognostic relevance of proliferation-related miRNAs in pancreatic neuroendocrine neoplasms

Eur J Endocrinol 2018 10 1;179(4):219-228. Epub 2018 Oct 1.

‘Lendület’ Hereditary Endocrine Tumours Research Group, Hungarian Academy of Sciences – Semmelweis University, Budapest, Hungary

Objective: Pancreatic neuroendocrine neoplasms (PanNENs) are rare tumors arising from the endocrine pancreas; however, their prognosis differs significantly upon their proliferative state, which is characterized by histopathological grading. MiRNAs are small, noncoding RNAs posttranscriptionally regulating gene expression. Our aim was to identify miRNAs with altered expression upon proliferation which can be used as prognostic biomarkers in PanNENs. Read More

View Article

Download full-text PDF

Source
https://eje.bioscientifica.com/view/journals/eje/179/4/EJE-1
Publisher Site
http://dx.doi.org/10.1530/EJE-18-0305DOI Listing
October 2018
13 Reads

Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms.

Neuroendocrinology 2019 3;108(1):26-36. Epub 2018 Oct 3.

Gastrointestinal and Neuroendocrine Oncology Unit, European Institute of Oncology (IEO), Milan, Italy.

Recently, the European Neuroendocrine Tumor Society (ENETS) held working sessions composed of members of the advisory board and other neuroendocrine neoplasm (NEN) experts to attempt to identify unmet needs in NENs in different locations or with advanced/poorly differentiated NENs. This report briefly summarizes the main proposed areas of unmet needs in patients with functional and nonfunctional pancreatic NENs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000494258DOI Listing
October 2018
7 Reads
4.373 Impact Factor

A "Clearer" View of Pancreatic Pathology: A Review of Tissue Clearing and Advanced Microscopy Techniques.

Adv Anat Pathol 2019 Jan;26(1):31-39

Departments of Pathology.

Although pathologic lesions in the pancreas are 3-dimensional (3D) complex structures, we currently use thin 2D hematoxylin and eosin stained slides to study and diagnose pancreatic pathology. Two technologies, tissue clearing and advanced microscopy, have recently converged, and when used together they open the remarkable world of 3D anatomy and pathology to pathologists. Advances in tissue clearing and antibody penetration now make even dense fibrotic tissues amenable to clearing, and light sheet and confocal microscopies allow labeled cells deep within these cleared tissues to be visualized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000215DOI Listing
January 2019
12 Reads

Unmet Needs in Appendiceal Neuroendocrine Neoplasms.

Neuroendocrinology 2019 20;108(1):37-44. Epub 2018 Sep 20.

Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France.

Appendiceal neuroendocrine neoplasms (ANEN) are mostly discovered coincidentally during appendicectomy and usually have a benign clinical course; thus, appendicectomy alone is considered curative. However, in some cases, a malignant potential is suspected, and therefore additional operations such as completion right hemicolectomy are considered. The existing European Neuroendocrine Tumour Society (ENETS) guidelines provide useful data about epidemiology and prognosis, as well as practical recommendations with regards to the risk factors for a more aggressive disease course and the indications for a secondary operation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493894DOI Listing
September 2018
2 Reads
4.373 Impact Factor

The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations.

J Clin Med 2018 Sep 13;7(9). Epub 2018 Sep 13.

Department of Pathology, University Health Network, Toronto, ON M5G 2C4, Canada.

Paragangliomas are neuroendocrine neoplasms, derived from paraganglia of the sympathetic and parasympathetic nervous systems. They are most commonly identified in the head and neck, being most frequent in the carotid body, followed by jugulotympanic paraganglia, vagal nerve and ganglion nodosum, as well as laryngeal paraganglia. Abdominal sites include the well-known urinary bladder tumors that originate in the Organ of Zuckerkandl. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/2077-0383/7/9/280
Publisher Site
http://dx.doi.org/10.3390/jcm7090280DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162705PMC
September 2018
19 Reads

Perioperative complications of adrenalectomy - 12 years of experience from a single center/teaching hospital and literature review.

Arch Med Sci 2018 Aug 20;14(5):1010-1019. Epub 2018 Jul 20.

1 Department and Clinic of General, Gastroenterological and Endocrine Surgery, Wroclaw Medical University, Wroclaw, Poland.

Introduction: The perioperative complication rate of adrenalectomy varies between 1.7% and 30.7% in the medical literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/aoms.2018.77257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111348PMC
August 2018
22 Reads

Solid pseudopapillary neoplasms of the pancreas do not express major pancreatic markers in pediatric patients.

Hum Pathol 2019 Jan 18;83:29-35. Epub 2018 Aug 18.

Department of Pathology, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, and Université Paris Descartes, 75015 Paris, France. Electronic address:

Solid pseudopapillary neoplasms (SPNs) of the pancreas are classified as "exocrine" pancreatic tumors by the World Health Organization. However, despite numerous studies using immunohistochemistry, electron microscopy, animal models, and molecular biology, the histogenesis of SPN remains unclear. At the same time, our knowledge of human pancreas development has significantly increased. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2018.08.010DOI Listing
January 2019
3 Reads

Solid Pseudo-Papillary Tumor Mimicking as Complicated Pseudocyst: Multimodality Imaging and Pathological Correlation.

Clin Nucl Med 2018 Oct;43(10):e368-e371

Radiology, Medical Imaging, Centre Hospitalier Universitaire Sainte-Justine, Montréal, Québec, Canada.

Pancreatic neoplasm is very rare in the pediatric population. Malignant tumors represent less than 0.2% of pediatric cancer-related mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002225DOI Listing
October 2018
4 Reads

[Endocrine Organ Dysfunction with Immune-Checkpoint Inhibitors].

Gan To Kagaku Ryoho 2018 Jul;45(7):1031-1035

The First Dept. of Medicine, Dept. of Diabetes, Endocrinology and Metabolism, Wakayama Medical University.

Cytotoxic T-lymphocyte associated antigen 4(CTLA-4), programmed death 1(PD-1), and programmed death-ligand 1 (PD-L1)are referred to as immune-checkpoints. CTLA-4 is located on the surface of activated T-cells, therefore inhibiting binding of CD28 to B7 molecule on antigen presenting cells. The CTLA-4 pathway predominantly acts in lymph nodes. Read More

View Article

Download full-text PDF

Source
July 2018
18 Reads

Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Clin Diabetes Endocrinol 2018 11;4:16. Epub 2018 Jul 11.

Neuroendocrine Tumor Unit, Endocrinology and Metabolism Department, Division of Medicine, Hadassah-Hebrew University Medical Center, P.O.B. 12000, 91120 Jerusalem, Israel.

Background: Neuroendocrine tumors (NETs) are rare neoplasms, with an estimated annual incidence of ~ 6.9/100,000. NETs arise throughout the body from cells of the diffuse endocrine system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40842-018-0066-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042326PMC
July 2018
10 Reads

Prognostic relevance of proliferation-related miRNAs in pancreatic neuroendocrine neoplasms.

Eur J Endocrinol 2018 Jul 13. Epub 2018 Jul 13.

A Patocs, "Lendulet" Hereditary Endocrine Tumors Research Group, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary.

Objective Pancreatic neuroendocrine neoplasms (PanNENs) are rare tumors arising from the endocrine pancreas, however their prognosis differs significantly upon their proliferative state which is characterized by histopathological grading. MiRNAs are small, noncoding RNAs posttranscriptionally regulating gene expression. Our aim was to identify miRNAs with altered expression upon proliferation which can be used as prognostic biomarkers in PanNENs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EJE-18-0305DOI Listing
July 2018
6 Reads

Ectopic insulinomas in the pelvis secondary to rectum neuroendocrine tumour.

BMJ Case Rep 2018 Jun 29;2018. Epub 2018 Jun 29.

Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.

We describe a middle-aged woman with recurrent hypoglycaemia, who confirmed with rectum G1 neuroendocrine tumour (NET) 6 years ago. Biochemical assay showed high concentration of serum insulin and C-peptide associated with hypoglycaemia. Because of recurrent hypoglycaemia in June 2015, she underwent a resection of the tail of the pancreas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-224281DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040560PMC
June 2018
20 Reads

Peptide-based sequestration of the adaptor protein Nck1 in pancreatic β cells enhances insulin biogenesis and protects against diabetogenic stresses.

J Biol Chem 2018 08 25;293(32):12516-12524. Epub 2018 Jun 25.

From the Research Institute of the McGill University Health Centre, Montreal, Quebec H4A 3J1, Canada,

One feature of diabetes is the failure of pancreatic β cells to produce insulin, but the molecular mechanisms leading to this failure remain unclear. Increasing evidence supports a role for protein kinase R-like endoplasmic reticulum kinase (PERK) in the development and function of healthy pancreatic β cells. Previously, our group identified the adaptor protein Nck1 as a negative regulator of PERK. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.RA118.002728DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093234PMC

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.

Diabetes 2018 08 24;67(8):1471-1480. Epub 2018 Jun 24.

Section of Endocrinology and Metabolism, Department of Internal Medicine, Yale University, New Haven, CT

Insulin-dependent diabetes may occur in patients with cancers who are treated with checkpoint inhibitors (CPIs). We reviewed cases occurring over a 6-year period at two academic institutions and identified 27 patients in whom this developed, or an incidence of 0.9%. Read More

View Article

Download full-text PDF

Source
http://diabetes.diabetesjournals.org/lookup/doi/10.2337/dbi1
Publisher Site
http://dx.doi.org/10.2337/dbi18-0002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054443PMC
August 2018
15 Reads

Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances.

Adv Anat Pathol 2019 Jan;26(1):13-30

Departments of Pathology, Massachusetts General Hospital, Boston, MA.

This review focuses on discussing the main modifications of the recently published 2017 WHO Classification of Neoplasms of the Neuroendocrine Pancreas (panNEN). Recent updates separate pancreatic neuroendocrine tumors into 2 broad categories: well-differentiated pancreatic neuroendocrine tumors (panNET) and poorly differentiated pancreatic neuroendocrine carcinoma (panNEC), and incorporates a new subcategory of "well-differentiated high-grade NET (G3)" to the well-differentiated NET category. This new classification algorithm aims to improve the prediction of clinical outcomes and survival and help clinicians select better therapeutic strategies for patient care and management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000201DOI Listing
January 2019
26 Reads

Incidental Neuroendocrine Tumor Discovered After Total Pancreatectomy Intended for Islet Autotransplantation: Important Considerations for Surgical Decision-Making.

Pancreas 2018 07;47(6):778-782

Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota Medical School, Minneapolis, MN.

Total pancreatectomy (TP) is a treatment option for patients experiencing chronic pancreatitis (CP) refractory to medical management. Patients who are candidates for TP benefit from islet autotransplantation (IAT), which preserves available β-cell mass and thereby reduces the risk of brittle diabetes. Malignancy is an absolute contraindication for IAT to prevent the transplantation of occult malignant cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPA.0000000000001069DOI Listing
July 2018
5 Reads

Quantitative determination of pancreas size using anatomical landmarks and its clinical relevance: A systematic literature review.

Clin Anat 2018 Sep 18;31(6):913-926. Epub 2018 Oct 18.

Department of Surgery, University of Auckland, Auckland, 1023, New Zealand.

There have been many reports of altered pancreas size in diseases of the endocrine and exocrine pancreas, but few attempts to quantify such changes. The aim of this study was to conduct a systematic literature review, documenting the methodology, and quantitative data in studies reporting on pancreas size. Three electronic databases (Embase, Scopus, and MEDLINE) were searched by two reviewers independently. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ca.23217DOI Listing
September 2018
5 Reads

Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift.

Therap Adv Gastroenterol 2018 27;11:1756284818775054. Epub 2018 May 27.

Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

Stem cells are considered the origin of neoplasms in general, and malignant tumours in particular, and the stage at which the stem cells stop their differentiation determines the degree of malignancy. However, there is increasing evidence supporting an alternative paradigm. Tumours may develop by dedifferentiation from mature cells able to proliferate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756284818775054DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974566PMC
May 2018
18 Reads

[Insulinoma found in patient with apparent mental disorder: a case report].

Rev Gastroenterol Peru 2018 Jan-Mar;38(1):82-84

Facultad de Medicina, Universidad Nacional de San Agustín. Arequipa, Perú; Sociedad Científica de Estudiantes de Medicina Agustinos (SOCIEMA). Arequipa, Perú.

Pancreatic Insulinoma is a neuroendocrine tumor of the beta cells of the islets of Langerhans, has an incidence of 4 cases per 1 000 000 persons. We report the case of a 36-year-old woman with altered behavior associated with melancholy. Psychiatry describes an abnormal mental examination and diagnosed double depression; however, the patient had the Whipple triad and insulin/glucose ratio higher than 0. Read More

View Article

Download full-text PDF

Source
November 2018
5 Reads

Molecular Diagnostics in the Neoplasms of the Pancreas, Liver, Gallbladder, and Extrahepatic Biliary Tract: 2018 Update.

Clin Lab Med 2018 06;38(2):367-384

Department of Pathology and Anatomical Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo-SUNY, Buffalo General Hospital A-701, 100 High Street, Buffalo, NY 14203, USA. Electronic address:

Pancreatic neoplasms, including ductal adenocarcinoma, solid pseudopapillary neoplasm, pancreatic endocrine neoplasms, acinar cell carcinoma, and pancreatoblastoma, are associated with different genetic abnormalities. Hepatic adenomas with beta-catenin exon 3 mutation are associated with a high risk of malignancy. Hepatic adenoma with arginosuccinate synthetase 1 expression or sonic hedgehog mutations are associated with a risk of bleeding. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cll.2018.03.003DOI Listing
June 2018
11 Reads

An unusual finding in a desmoid-type fibromatosis of the pancreas: a case report and review of the literature.

J Med Case Rep 2018 May 12;12(1):123. Epub 2018 May 12.

Department of Endocrine and Breast Surgery, First Affiliated Hospital of Chongqing Medical University, No.1 Yixueyuan Rd, Yuzhong District, Chongqing, 400016, People's Republic of China.

Background: Desmoid-type fibromatoses are rare benign and fibrous tumors that account for approximately 0.03% of total neoplasms. Within this category of neoplasms, pancreatic desmoid-type fibromatosis is an extremely rare subgroup, accounting for approximately 5% of desmoid-type fibromatoses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13256-018-1635-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948877PMC
May 2018
5 Reads

Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.

Nucl Med Rev Cent East Eur 2018 ;21(2)

Maria Sklodowska-Curie Memorial Cancer Center and Institiute of Oncology, Wawelska 15, 02-034 Warszawa, Poland.

Peptide Receptor Radionuclide Therapy (PRRT) is a form of molecular targeted therapy which is performed by using a small peptide (somatostatin analogue - SSA) that is coupled with a radionuclide beta emitting radiation. PRRT is a nuclear medicine for the systemic treatment of non-resectable, metastasized well/moderately differentiated, neuroendocrine tumours (NET) with overexpression of somatostatin receptor. These types of tumours include gastroenteropancreatic neoplasm (GEP-NENs), e. Read More

View Article

Download full-text PDF

Source
https://journals.viamedica.pl/nuclear_medicine_review/articl
Publisher Site
http://dx.doi.org/10.5603/NMR.2018.0019DOI Listing
September 2018
14 Reads

Proteins of the retinoblastoma pathway, FEN1 and MGMT are novel potential prognostic biomarkers in pancreatic adenocarcinoma.

Pathol Res Pract 2018 Jun 1;214(6):840-847. Epub 2018 May 1.

Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Finland. Electronic address:

Background: We studied the expression of some major proteins involved in cell-cycle regulation and DNA repair, the roles of which are not well known in pancreatic ductal adenocarcinoma (PDAC), but which have a significant impact on carcinogenesis of many other cancers.

Methods: We immunohistochemically assessed expression levels of the cell-cycle regulators Rb1, p16 and cyclin-dependent kinase 4 (CDK4), and the DNA repair enzymes O6-methylguanine-DNA-alkyltransferase (MGMT) and flap endonuclease-1 (FEN1) separately in malignant tissue and benign tissue from resection margins in 102 cases of PDAC. Nearly all (95. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03440338183015
Publisher Site
http://dx.doi.org/10.1016/j.prp.2018.04.016DOI Listing
June 2018
7 Reads

Association of Androgen Excess with Glucose Intolerance in Women with Polycystic Ovary Syndrome.

Biomed Res Int 2018 8;2018:6869705. Epub 2018 Mar 8.

Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, No. 321 Zhongshan Road, Nanjing 210008, China.

Women with polycystic ovary syndrome (PCOS) show high prevalence of glucose intolerance. This study aimed to investigate the association of androgen excess with glucose intolerance in PCOS. A total of 378 women with PCOS participated in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/6869705DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863307PMC
September 2018
4 Reads

Endoscopic Ultrasound Features of Multiple Endocrine Neoplasia Type 1-Related versus Sporadic Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Study.

Digestion 2018 26;98(2):112-118. Epub 2018 Apr 26.

Division of Endocrinology and Diabetology, University Hospital, Philipp's University, Marburg, Germany.

Aim: Pancreatic neuroendocrine tumors (pNETs) can occur in patients with a familial syndrome either as multiple endocrine neoplasia type 1 (MEN-1) or as sporadic tumors. Endoscopic ultrasound (EUS) has become one of the first-line investigations for pNET characterization. The ultrasonographic features of pNETs may differ depending on the familial versus sporadic pathogenesis of the tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000487939DOI Listing
November 2018
4 Reads

Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.

Eur J Cancer 2018 06 23;96:91-104. Epub 2018 Apr 23.

Department of Radiology, Gustave Roussy Cancer Campus, Villejuif, France; Université Paris-Saclay, Paris, France.

Background: Programmed death receptor-1 blocking antibodies (anti-PD1) are a new standard of care in many cancer types. Patients benefit from improved survival but have the risk of immune-related adverse events (irAE). We evaluated if medical imaging procedures, used for anti-tumour response assessment, can detect irAEs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.03.006DOI Listing
June 2018
42 Reads

Metastatic neuroendocrine pancreatic tumor - Case report.

J Med Life 2018 Jan-Mar;11(1):57-61

Gastroenterology Department, Fundeni Clinical Institute, Bucharest, Romania "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

Pancreatic neuroendocrine tumors (NETs) are rare neoplasms that develop from the endocrine tissues of the pancreas. They have a better overall prognosis than pancreatic adenocarcinoma. However, all commonly used classification systems reflect a separation between more indolent, well-differentiated tumors and far more aggressive poorly differentiated types that behave clinically more like small-cell carcinoma of the lung. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909947PMC
June 2018
23 Reads

Pancreatic Neuroendocrine Tumors and Intraductal Papillary Mucinous Neoplasm of the Pancreas: A Systematic Review.

Pancreas 2018 May/Jun;47(5):551-555

From the Department of General and Digestive Surgery, University Hospital of Guadalajara, Guadalajara, Spain.

Objectives: This study aimed to identify factors that explain the association of intraductal papillary mucinous neoplasms-pancreatic neuroendocrine tumors (IPMNs-PNETs), radiological characteristics, and factors that might guide therapy.

Methods: We performed a systematic review of the literature to search for articles on concurrent IPMN-PNET, mixed endocrine-exocrine pancreatic tumors, and/or PNET with an intraductal growth pattern.

Results: A review of the literature suggests that there is some confusion about association of IPMNs-PNETs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPA.0000000000001048DOI Listing
October 2018
4 Reads

[Surgical strategies for small sporadic neuroendocrine pancreatic tumors].

Authors:
K Holzer

Chirurg 2018 Jun;89(6):422-427

Sektionsleitung Endokrine Chirurgie, Klinik für Viszeral‑, Thorax- und Gefäßchirurgie, Universitätsklinikum Marburg, Baldingerstraße, 35043, Marburg, Deutschland.

Small (<2 cm) sporadic neuroendocrine pancreatic neoplasms (pNENs) are a heterogeneous group of neoplasms, which can be separated into functionally active or non-functional tumors. Functionally active pNENs release various hormones, such as insulin, gastrin, glucagon and vasoactive intestinal hormones and therefore lead to severe symptoms independent of their size. The main symptoms include hypoglycemia, coma (insulinoma), diarrhea (gastrinoma, VIPoma), intestinal ulcers (gastrinoma) and hyperglycemia (glucagonoma). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00104-018-0632-3DOI Listing
June 2018
2 Reads

Surgical resection of neuroendocrine tumors of the pancreas (pNETs) by minimally invasive surgery: the laparoscopic approach.

Gland Surg 2018 Feb;7(1):12-19

Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan.

Neuroendocrine tumors of the pancreas (pNETs) are a rare group of neoplasms that originate from the endocrine portion of the pancreas. Tumors that either secrete or do not secrete compounds, resulting in symptoms, can be classified as functioning and non-functioning pNETs, respectively. The prevalence of such tumors has recently increased due to the use of more sensitive imaging techniques, such as multidetector computed tomography, magnetic resonance imaging and endoscopic ultrasound. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/gs.2017.11.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876680PMC
February 2018
3 Reads

Conformational switching within dynamic oligomers underpins toxic gain-of-function by diabetes-associated amyloid.

Nat Commun 2018 04 3;9(1):1312. Epub 2018 Apr 3.

Department of Molecular Biophysics and Biochemistry, Department of Chemical and Environmental Engineering, Yale University, 260 Whitney Avenue, New Haven, CT, 06520-8114, USA.

Peptide mediated gain-of-toxic function is central to pathology in Alzheimer's, Parkinson's and diabetes. In each system, self-assembly into oligomers is observed and can also result in poration of artificial membranes. Structural requirements for poration and the relationship of structure to cytotoxicity is unaddressed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-03651-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882805PMC
April 2018
8 Reads
2 Citations
10.740 Impact Factor

Metastatic pheochromocytoma in MEN 2A: A rare association.

BMJ Case Rep 2018 Mar 28;2018. Epub 2018 Mar 28.

Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

A 45-year-old woman was diagnosed as having multiple endocrine neoplasia type 2A in 2014. She had bilateral pheochromocytoma, medullary thyroid carcinoma and biopsy-proven cutaneous lichen amyloidosis in the interscapular area. She underwent bilateral adrenalectomy; following which, she achieved clinical and biochemical remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2017-222758DOI Listing
March 2018
15 Reads

Diagnosis and treatment of solid-pseudopapillary tumors of the pancreas: A single institution experience with 97 cases.

Pancreatology 2018 Jun 24;18(4):415-419. Epub 2017 Dec 24.

Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. Electronic address:

Background/objectives: We evaluated the diagnoses and surgical management of solid pseudopapillary tumors of the pancreas (SPTP) in a single center setting.

Methods: Demographic details, clinical presentations, imaging features, surgical strategies, and pathological findings of 97 consecutive patients who underwent surgery for pathologically confirmed SPTP between 2008 and 2016 were analyzed retrospectively.

Results: A total of 97 patients with SPTP accounted for 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pan.2017.12.012DOI Listing
June 2018
5 Reads

Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.

Leukemia 2018 Oct 30;32(10):2203-2210. Epub 2018 Jan 30.

Department of Medicine, Division of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.

To determine the risk of a wide range of second malignancies in patients with myeloproliferative neoplasms (MPNs), we conducted a large population-based study and compared the results to matched controls. From national Swedish registers, 9379 patients with MPNs diagnosed between 1973 and 2009, and 35,682 matched controls were identified as well as information on second malignancies, with follow-up until 2010. Hazard ratios (HRs) with 95 % confidence intervals (CIs) were calculated using Cox regression and a flexible parametric model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0027-yDOI Listing
October 2018
13 Reads

Predictive factors of endocrine and exocrine insufficiency after resection of a benign tumour of the pancreas.

Ann Endocrinol (Paris) 2018 Apr 8;79(2):53-61. Epub 2018 Mar 8.

CHU de Poitiers, service de chirurgie viscérale, 2, rue de la Milétrie, 86000 Poitiers, France.

Background: The aim of the present study is to evaluate the risk factors of endocrine and exocrine insufficiency occurring few years after pancreatic resections in a consecutive series of patients who underwent pancreatoduodenectomy (PD), left pancreatectomy (LP) or enucleation for benign neoplasms at a referral centre.

Methods: Pancreatic exocrine insufficiency (PEI) was defined by the onset of steatorrhea associated with weight loss, and endocrine insufficiency was determinate by fasting plasma glucose. Association between pancreatic insufficiency and clinical, pathological, and perioperative features was studied using univariate and multivariate Cox regression analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2017.10.003DOI Listing
April 2018
6 Reads

Enucleation of pancreatic solid pseudopapillary neoplasm: Short-term and long-term outcomes from a 7-year large single-center experience.

Eur J Surg Oncol 2018 05 6;44(5):644-650. Epub 2018 Feb 6.

Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China. Electronic address:

Background: Enucleation is increasingly used for pancreatic solid pseudopapillary neoplasm (SPN) to preserve function of the pancreas. The data was limited due to rarity of this low-grade neoplasm. We sought to describe the indications, operative technique, short and long-term outcomes after enucleation with largest series of enucleated SPNs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2018.01.085DOI Listing
May 2018
5 Reads

Lipid accelerating the fibril of islet amyloid polypeptide aggravated the pancreatic islet injury in vitro and in vivo.

Lipids Health Dis 2018 Mar 9;17(1):42. Epub 2018 Mar 9.

Institute of Anatomy and Histology & Embryology, Neuroscience, School of Basic Medical Sciences, Lanzhou University, No. 199 of Donggang West Road, Lanzhou City, Gansu Province, 730000, People's Republic of China.

Background: The fibrillation of islet amyloid polypeptide (IAPP) triggered the amyloid deposition, then enhanced the loss of the pancreatic islet mass. However, it is not clear what factor is the determinant in development of the fibril formation. The aim of this study is to investigate the effects of lipid on IAPP fibril and its injury on pancreatic islet. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12944-018-0694-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845206PMC
March 2018
8 Reads

Robot-assisted duodenum-preserving pancreatic head resection with pancreaticogastrostomy for benign or premalignant pancreatic head lesions: a single-centre experience.

Int J Med Robot 2018 Aug 2;14(4):e1903. Epub 2018 Mar 2.

Department of Pancreatic Surgery, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.

Background: The purpose of this study was to compare short- and long-term outcomes of modified robot-assisted duodenum-preserving pancreatic head resection (RA-DPPHR) versus robot-assisted pancreaticoduodenectomy (RA-PD).

Methods: Matched for age, sex, ASA classification, tumour size, history of abdominal surgery and pathological type, 34 patients undergoing RA-DPPHR and 34 patients undergoing RA-PD between January 2010 and December 2016 were retrospectively analyzed.

Results: The RA-DPPHR group had shorter surgical time (188. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/rcs.1903DOI Listing
August 2018
31 Reads

Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.

Gastroenterology 2018 06 2;154(8):2060-2063.e8. Epub 2018 Mar 2.

Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Electronic address:

Despite prognostic grading and staging systems, it is a challenge to predict outcomes for patients with pancreatic neuroendocrine tumors (PanNETs). Sequencing studies of PanNETs have identified alterations in death domain-associated protein (DAXX) and alpha-thalassemia/mental retardation X-linked chromatin remodeler (ATRX). In tumors, mutations in DAXX or ATRX and corresponding loss of protein expression correlate with shorter times of disease-free survival and disease-specific survival of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2018.02.026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985217PMC
June 2018
18 Reads

Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment.

BMC Endocr Disord 2018 Feb 27;18(1):14. Epub 2018 Feb 27.

Department of Endocrinology and Metabolism, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 160 Pujian Road, Shanghai, 200127, China.

Background: Impaired insulin activity in women with polycystic ovary syndrome might differ from that seen in type 2 diabetes mellitus without polycystic ovary syndrome. This study was designed to compare the effects of treatment with metformin, saxagliptin, and their combination in newly diagnosed women with type 2 diabetes mellitus and polycystic ovary syndrome in China.

Methods: A total of 75 newly diagnosed patients from Shanghai, China with type 2 diabetes mellitus and polycystic ovary syndrome were included in this randomized, parallel, open-label study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12902-018-0243-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828487PMC
February 2018
14 Reads

Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer.

Mol Cancer 2018 02 23;17(1):66. Epub 2018 Feb 23.

Department of Surgery, Klinikum rechts der Isar, Technical University Munich, München, Germany.

Pancreatic ductal adenocarcinoma (PDAC) is unrivalled the deadliest gastrointestinal cancer in the western world. There is substantial evidence implying that insulin and insulin-like growth factor (IGF) signaling axis prompt PDAC into an advanced stage by enhancing tumor growth, metastasis and by driving therapy resistance. Numerous efforts have been made to block Insulin/IGF signaling pathway in cancer therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-018-0806-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824531PMC
February 2018
4 Reads